LONDON: Syncona Ltd’s portfolio company Achilles Therapeutics plc has announced the pricing of its initial public offering (IPO) in the United States of 9.75 million American Depositary Shares (ADSs), at an initial public offering price of $18 per ADS for total gross proceeds of approximately $175.5 million. All ADSs sold in the IPO were…
SYDNEY: Piedmont Lithium Limited plans to conduct a U.S. public offering of up to 1.5 million of its American Depositary Shares (ADSs), with each ADS representing 100 of its ordinary shares. J.P. Morgan, Evercore ISI and Canaccord Genuity are acting as joint book-runners and lead underwriters for the offering. Piedmont intends to grant the…
OSLO: IDEX Biometrics ASA announced that the Company will list American Depositary Shares (ADSs) each representing 75 ordinary shares of the Company on the Nasdaq Capital Market. Nasdaq has approved the ADSs for listing, and they are expected to begin trading under the symbol “IDBA” on 1 March 2021, subject to approval by the…